Genetic Technologies Osake

Genetic Technologies EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Genetic Technologies (GTG.AX) 13.8.2026 päivämäärällä on −10,08 M AUD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −9,52 M AUD — muutos 5,90 % (matalampi).

EBITDA

−10,08 MAUD

YoY

5,90%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Genetic Technologies on 2026 −10,08 M AUD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Genetic Technologies oli 2025 −9,52 M AUD. Se laskee 5,90% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Genetic Technologies Osakeanalyysi

Mitä Genetic Technologies tekee? Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Genetic Technologies osakkeesta

Yhtiön Genetic Technologies EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −10,08 M AUD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Genetic Technologies muuttui arvosta −9,52 M AUD arvoon −10,08 M AUD, mikä edustaa 5,90 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Genetic Technologies:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n AUD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Genetic Technologies historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Genetic Technologies

Kaikki tunnusluvut — Genetic Technologies